Revance Therapeutics (RVNC) to Offer Common Stock
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/3/2026
- Dow jumps to record closing high after soft US jobs data, Nasdaq down with chip shares
- Goldman's Garrett sees investors dialing back tech exposure into H2
- AI chip winners may face tougher road ahead as hyperscalers catch up: JPM
- Oil gains on short-covering buys ahead of US holiday
- Rivian stock jumps 5% on raised delivery outlook
- Analysis-Excommunications show a Pope Leo unafraid of making firm decisions
- Dow jumps to record closing high after soft US jobs data, Nasdaq down with chip shares
- Canaccord Starts Infleqtion, Inc (INFQ) at Buy
- Jersey Mike's Subs files for IPO on NYSE under ticker JMKE
- Albanian police use teargas to disperse anti-graft demonstrators
Revance Announces Proposed Public Offering of Common Stock
December 3, 2019 4:01 PM ESTNEWARK, Calif.,--(BUSINESS WIRE)-- Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions (Revance or the Company), today announced a proposed underwritten public offering of its common stock. The Company intends to use the net proceeds received from its offering of common stock to continue to fund the commercialization of DAXI, and the remainder for working capital, research and development and general corporate purposes. The offering is subject to market and other conditions, and there can be no assurance as to... More
